Despite major advances in prophylaxis and supportive care, hemophilia continues to disrupt daily life, limit function, and compromise long-term well-being for many patients. Joint bleeding, subclinical bleeding, and progressive arthropathy remain important concerns, even in the modern treatment era, with ongoing impacts on pain, mobility, and health-related quality of life. Clinicians must keep pace with shifting treatment strategies, including updated factor VIII (FVIII) target levels from recent guidelines to mediate bleeding protection and the growing role of rebalancing agents. To deliver optimal care, healthcare professionals need a clearer understanding of how to preserve joint health across the lifespan, apply evolving treatment targets judiciously, and select and integrate therapies in ways that reflect the latest clinical evidence, patient priorities, and treatment burden. This activity addresses these needs through expert-led discussions focused on long-term joint outcomes, FVIII-targeted treatment strategies, and the practical clinical integration of rebalancing agents.

Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

This series of brief episodes examines Alzheimer’s disease (AD) as an integrated neurodegenerative and neuropsychiatric syndrome. Drs. Marwan Sabbagh and Dani Cabral highlight challenges in clinical phenotyping and the consequences of treating neuropsychiatric symptoms (NPS) as separate comorbidities. The faculty also review emerging therapeutic approaches, including tau-targeting therapy for Alzheimer’s disease, as well as novel treatments for agitation and related NPS.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.